Veit Bücklein, Dr Med, on Research Trends in Hematological Malignancy Cell Therapy
January 23rd 2024The postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed research he was excited to see at ASH 2023 and in the field in general.
Sukumar Nagendran, MD, on the Potential of TSHA-102 in Pediatric Patients With Rett Syndrome
January 21st 2024The president and head of R&D at Taysha Gene Therapies discussed his expectation that younger patients my see even better results with the company’s gene therapy than the adult patients treated so far.
Veit Bücklein, Dr Med, on Looking Closer Into Differences in Response, Hematotoxicity After CAR T
January 9th 2024The postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed further research his group is conducting with cell therapy.
Gregory W. Roloff, MD, on Confirming Durable Efficacy of Brexu-Cel and Maintenance Therapy in B-ALL
January 7th 2024The chief hematology/oncology fellow at University of Chicago discussed real-world experience data and new analyses of patients with B-cell acute lymphoblastic leukemia treated with brexu-cel.